Financial Performance - In Q3 2025, the company's revenue increased by 2.3% year-on-year, with gross margin rising nearly 4 percentage points to 72.77%, and net loss significantly narrowed [2] - In Q2 2025, revenue reached 149 million RMB, a 10% year-on-year growth, marking six consecutive quarters of Non-GAAP profitability, which raised market expectations for a profitability turning point and led to a temporary stock price increase from October to November 2025 [2] Stock Performance - Since February 2026, the stock price has experienced increased volatility, with an 11.04% rise on February 6, followed by a continuous decline from February 9 to 11, closing at $28.60 on February 11, with a total market capitalization of $308 million, likely influenced by profit-taking and market sentiment fluctuations [3] Industry Policy and Environment - Tumor gene testing is one of the fastest-growing sectors in the global in vitro diagnostics field, with leading companies in the U.S. experiencing significant stock price increases and industry revenue growth rates of 15%-35% in 2025 [4] - As a leader in companion diagnostics in China, the company’s multi-cancer early detection product "Ran Xiao An" and MRD technology "Lang Wei" have gained international recognition, and the OncoGuide system, in collaboration with AstraZeneca, has been approved in Japan, potentially opening up overseas markets [4] - In December 2025, China released evaluation guidelines for tumor gene testing reagents and pathology service pricing projects, providing institutional support for the industry [4] Company Valuation - The company's stock price increased by 207% in 2025, but its price-to-sales ratio is only 3 times, lower than global peers, as investors reassess its value following performance improvements, particularly with in-hospital testing business maintaining a stable 55% share and optimizing business structure [5]